Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

Figure 4

Outcomes of the 65 patients included according to subgroup classification based on the cause of treatment discontinuation and outcomes after second-course anti-PD-1. Of the 65 patients who discontinued anti-PD-1 for other reasons than PD, 12 patients relapsed and 9 of them received a second-course anti-PD-1. $ comprises 4 CR and 24 PR or SD as best response while on treatment. All patients had PR or SD as best response.